Stuart McCracken

1.8k total citations
37 papers, 1.0k citations indexed

About

Stuart McCracken is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Stuart McCracken has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 16 papers in Molecular Biology and 12 papers in Surgery. Recurrent topics in Stuart McCracken's work include Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (11 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Stuart McCracken is often cited by papers focused on Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (11 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Stuart McCracken collaborates with scholars based in United Kingdom, Netherlands and France. Stuart McCracken's co-authors include Craig Robson, Luke Gaughan, Hing Y. Leung, Marie E. Mathers, Tim Dudderidge, Joanne Edwards, Jacqueline Stockley, Ian R. Logan, Vasileia Sapountzi and David E. Neal and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stuart McCracken

34 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stuart McCracken United Kingdom 18 612 375 208 149 134 37 1.0k
Claudia Hube‐Magg Germany 21 630 1.0× 370 1.0× 260 1.3× 300 2.0× 79 0.6× 60 1.0k
Hidetoshi Kuruma Japan 19 544 0.9× 650 1.7× 257 1.2× 225 1.5× 61 0.5× 41 1.1k
Mareyuki Endoh Japan 18 306 0.5× 195 0.5× 187 0.9× 158 1.1× 143 1.1× 33 786
Hiroshi Sootome Japan 8 808 1.3× 129 0.3× 266 1.3× 120 0.8× 104 0.8× 27 1.0k
Lou Savas United States 7 548 0.9× 233 0.6× 145 0.7× 173 1.2× 60 0.4× 10 822
Maria Christina Tsourlakis Germany 21 752 1.2× 399 1.1× 192 0.9× 319 2.1× 89 0.7× 38 1.0k
Zizhen Feng China 12 671 1.1× 140 0.4× 272 1.3× 145 1.0× 137 1.0× 23 1.0k
Martina Kluth Germany 22 768 1.3× 644 1.7× 327 1.6× 415 2.8× 110 0.8× 75 1.3k
Judith A. Finlay United States 17 340 0.6× 776 2.1× 111 0.5× 110 0.7× 84 0.6× 30 1.2k
Katharina König Germany 14 564 0.9× 231 0.6× 357 1.7× 246 1.7× 121 0.9× 20 1.0k

Countries citing papers authored by Stuart McCracken

Since Specialization
Citations

This map shows the geographic impact of Stuart McCracken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart McCracken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart McCracken more than expected).

Fields of papers citing papers by Stuart McCracken

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart McCracken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart McCracken. The network helps show where Stuart McCracken may publish in the future.

Co-authorship network of co-authors of Stuart McCracken

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart McCracken. A scholar is included among the top collaborators of Stuart McCracken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart McCracken. Stuart McCracken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rouprêt, Morgan, Paolo Gontero, Stuart McCracken, et al.. (2022). Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non–muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. European Urology Focus. 8(6). 1643–1649. 16 indexed citations
3.
4.
Thurtle, David, Valerie Jenkins, Alexandra L. J. Freeman, et al.. (2021). Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial. European Urology. 80(5). 661–669. 11 indexed citations
5.
Reddy, Deepika, Taimur T. Shah, Tim Dudderidge, et al.. (2020). Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. Contemporary Clinical Trials. 93. 105999–105999. 17 indexed citations
6.
7.
Shah, Taimur T., Max Peters, David Eldred‐Evans, et al.. (2019). Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. European Urology. 76(1). 98–105. 97 indexed citations
8.
Shah, Taimur T., Max Peters, Saiful Miah, et al.. (2019). Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. European Urology Focus. 7(2). 301–308. 10 indexed citations
9.
Nakjang, Sirintra, Stuart McCracken, Scott M. Dehm, et al.. (2019). A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. Nucleic Acids Research. 47(11). 5634–5647. 42 indexed citations
10.
McClurg, Urszula L., Stuart McCracken, Lisa M. Butler, Karl Riabowol, & Olivier Binda. (2018). Ex vivo Culture and Lentiviral Transduction of Benign Prostatic Hyperplasia (BPH) Samples. BIO-PROTOCOL. 8(21). 2 indexed citations
11.
McClurg, Urszula L., Joanne Edwards, Arash Nabbi, et al.. (2018). Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene. 37(34). 4679–4691. 36 indexed citations
12.
Gaughan, Luke, et al.. (2016). 41 The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets. European Urology Supplements. 15(3). e41–e41. 2 indexed citations
13.
Gao, Meiling, Rachana Patel, Imran Ahmad, et al.. (2012). SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Molecular Medicine. 4(8). 776–790. 37 indexed citations
14.
McCracken, Stuart, Janis Fleming, Imran Ahmad, et al.. (2011). ERK5 signalling in prostate cancer promotes an invasive phenotype. British Journal of Cancer. 104(4). 664–672. 73 indexed citations
15.
Brooke, Greg N., D. Alwyn Dart, David J. Mann, et al.. (2010). FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth. Cancer Research. 71(3). 914–924. 57 indexed citations
16.
Gaughan, Luke, Jacqueline Stockley, Nan Wang, et al.. (2010). Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Research. 39(4). 1266–1279. 103 indexed citations
17.
Campbell, G., et al.. (2007). A cautionary tale: delayed onset rhabdomyolysis due to erythromycin/simvastatin interaction. Age and Ageing. 36(5). 597–597. 8 indexed citations
18.
McCracken, Stuart, Rakesh Heer, Marie E. Mathers, et al.. (2007). Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene. 27(21). 2978–2988. 65 indexed citations
19.
Dudderidge, Tim, Stuart McCracken, Marco Loddo, et al.. (2007). Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. British Journal of Cancer. 96(9). 1384–1393. 35 indexed citations
20.
Mathers, Marie E., et al.. (2005). Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. British Journal of Cancer. 92(2). 320–327. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia Hube‐Magg Breakdown of academic impact, for papers by Hidetoshi Kuruma Breakdown of academic impact, for papers by Mareyuki Endoh Breakdown of academic impact, for papers by Hiroshi Sootome Breakdown of academic impact, for papers by Lou Savas Breakdown of academic impact, for papers by Maria Christina Tsourlakis Breakdown of academic impact, for papers by Zizhen Feng Breakdown of academic impact, for papers by Martina Kluth Breakdown of academic impact, for papers by Judith A. Finlay Breakdown of academic impact, for papers by Katharina König
Rankless by CCL
2026